Clinical Trials
15 trialsNCT05312840 2026-06-01
Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer
People's Hospital of Quzhou
Phase 4 Completed
NCT07279935 2026-06-01
REVIVE
AstraZeneca
Phase 4 Recruiting
NCT07405086 2026-05-22
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT06646471 2026-04-29
PROMETHEE
Groupe Francais De Pneumo-Cancerologie
Phase 4 Recruiting
NCT03340506 2026-04-20
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
NCT06330038 2026-04-20
GASTIVA
Samsung Medical Center
Phase 4 Recruiting
NCT06282874 2026-04-09
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Active not recruiting
NCT05110196 2026-04-07
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
Novartis
Phase 4 Completed
NCT05160922 2026-03-30
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT07469488 2026-03-13
AmiCARE
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4 Not yet recruiting
NCT03673332 2026-01-22
EPITOP-01
Institut Paoli-Calmettes
Phase 4 Terminated
NCT07320105 2026-01-06
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
Fujian Cancer Hospital
Phase 4 Recruiting
NCT05144997 2025-12-17
Lorlatinib Continuation Study
Pfizer
Phase 4 Active not recruiting
NCT05219162 2025-09-11
GPS
AstraZeneca
Phase 4 Completed
NCT03715205 2025-08-29
Keynote-593
Merck Sharp & Dohme LLC
Phase 4 Completed